

CLEAR OUTCOMES: SUBGROUP ANALYSIS BY SEX

A PRESPECIFIED, EXPLORATORY ANALYSIS OF BEMPEDOIC ACID BASED ON SEX

INDICATION¹

Bempedoic acid (NEXLETOL[®]) is indicated:

- To reduce the risk of myocardial infarction and coronary revascularization in adults who are unable to take recommended statin therapy (including those not taking a statin) with:
 - established cardiovascular disease (CVD), or
 - at high risk for a CVD event, but without established CVD.
- As an adjunct to diet, in combination with other LDL-C lowering therapies, or alone when concomitant LDL-C lowering therapy is not possible, to reduce LDL-C in adults with primary hyperlipidemia, including HeFH.

CLEAR Outcomes: Overall Population Study Design & Methodology^{2,3}



Patients **without established CVD** were considered at high risk for CVD based on meeting at least one of the following criteria:

- Type 1 or 2 diabetes in women >65 or men >60 years of age
- Reynolds Risk score $>30\%$ **OR** SCORE risk $>7.5\%$ over 10 years
- Any previous coronary artery calcium score of >400 AU

Patients **with established CVD** had documented history of at least one of the following:

- coronary artery disease
- symptomatic peripheral arterial disease
- cerebrovascular atherosclerotic disease

CLEAR Outcomes: Overall Population Primary Composite Endpoint³

In the total CLEAR Outcomes population, which included both primary (30%) and secondary (70%) prevention patients, the composite primary endpoint of the study (MACE-4) occurred in 819 patients (11.7%) in the bempedoic acid group vs. 927 patients (13.3%) in the placebo group; HR 0.87 (95% CI 0.79, 0.96), $P=0.004$

Summary of Safety¹

NEXLETOL is contraindicated in patients with a prior serious hypersensitivity reaction to bempedoic acid or any of the excipients. Serious hypersensitivity reactions, such as angioedema, have occurred.

Hyperuricemia: NEXLETOL may increase blood uric acid levels, which may lead to gout. Hyperuricemia may occur early in treatment and persist throughout treatment, returning to baseline following discontinuation of treatment. Assess uric acid levels periodically as clinically indicated. Monitor for signs and symptoms of hyperuricemia, and initiate treatment with urate-lowering drugs as appropriate.

Tendon Rupture: NEXLETOL is associated with an increased risk of tendon rupture or injury. Tendon rupture may occur more frequently in patients over 60 years of age, in those taking corticosteroid or fluoroquinolone drugs, in patients with renal failure, and in patients with previous tendon disorders. Discontinue NEXLETOL at the first sign of tendon rupture. Consider alternative therapy in patients who have a history of tendon disorders or tendon rupture.

The most common adverse reactions in the primary hyperlipidemia trials of NEXLETOL in $\geq 2\%$ of patients and greater than placebo were upper respiratory tract infection, muscle spasms, hyperuricemia, back pain, abdominal pain or discomfort, bronchitis, pain in extremity, anemia, and elevated liver enzymes.


The most common adverse reactions in the cardiovascular outcomes trial for NEXLETOL at an incidence of $\geq 2\%$ and 0.5% greater than placebo were hyperuricemia, renal impairment, anemia, elevated liver enzymes, muscle spasms, gout, and cholelithiasis.

References: 1. NEXLETOL[®] (bempedoic acid) US Full Prescribing Information. Esperion Therapeutics, Inc. 2. Nicholls SJ, et al. *Am Heart J.* 2021;235:104-112. 3. Nissen SE, et al. *N Engl J Med.* 2023;388(15):1353-1364. 4. Cho L, et al. *Circulation.* 2024 Apr 6. doi: 10.1161/CIRCULATIONAHA.123.067691. Epub ahead of print. PMID: 38581406.

Abbreviations: AE = adverse event; AU = Agatston units; LDL-C=low density lipoprotein; CVD = cardiovascular disease; HCP = health care provider; HeFH= heterozygous familial hypercholesterolemia; MACE=major adverse cardiovascular event; MACE-4: CV death, nonfatal MI, nonfatal stroke, coronary revascularization; MI= myocardial infarction; PCSK9 = proprotein convertase subtilisin/kexin type 9; QD = daily

Subgroup Analysis by Sex⁴

Incidence of MACE-4 by Sex^{3,4}



Number at Risk


	0	6	12	18	24	30	36	42	48	54
Females— BA	3361	3290	3226	3155	3083	3011	2618	1246	557	243
Females— Placebo	3379	3313	3239	3156	3071	2982	2557	1288	579	234
Males— BA	3631	3526	3428	3317	3210	3095	2639	1355	683	331
Males— Placebo	3599	3466	3340	3245	3135	3013	2548	1236	628	279

[‡]Interaction p-value is a test for heterogeneity between subgroups

Note: This Kaplan Meier (KM) Curve presents the time to first occurrence for each of the components of MACE-4.

Demographics⁴


N = 13,970



Limitations⁴

- This is a secondary analysis of a subpopulation in a larger randomized trial, such analyses can result in false-positive findings due to testing of multiple subgroups and may represent a play of chance
- The inclusion of patients who reported inability to tolerate statins resulted in a high mean baseline LDL-C level. The effects of cholesterol lowering on cardiovascular events in populations with lower pretreatment LDL-C was not studied.
- The trial selected patients using specific criteria for a high level of risk of a first cardiac event. Whether outcomes would be similar in patients identified using other criteria for an increased risk remains uncertain.

Mean Percent Change in LDL-C from Baseline³



Summary of Safety¹

Concomitant use of NEXLETOL with greater than 20 mg of simvastatin or 40 mg of pravastatin should be avoided due to the potential for increased risk of simvastatin- or pravastatin-related myopathy.

Discontinue NEXLETOL when pregnancy is recognized unless the benefits of therapy outweigh the potential risks to the fetus. Because of the potential for serious adverse reactions in a breast-fed infant, breastfeeding is not recommended during treatment with NEXLETOL.

Report pregnancies to Esperion Therapeutics, Inc. Adverse Event reporting line at 1-833-377-7633.



Cho LE, et al.
Clear Outcomes:
Sex Subgroup



Nissen SE, et al.
CLEAR Outcomes



NEXLETOL®
Prescribing
Information



Contact Us:
EsperionMedical.com

*All results are hypothesis generating and are descriptive in nature instead of confirmatory. Multiplicity is not adjusted/corrected.